End2End Genomics LLC

Biotech · Private

Automated pipeline and methods for low-cost de novo genome assembly from linked-read sequencing data

e2egenomics.com →
Grants
$408K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Cost effective high-quality genome assembly for non-model organisms$204,240
Federal grantDepartment of Health and Human Services · Phase I · Cost effective high quality genome assembly for non model organisms$204,240
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2995NeuroCycle Therapeutics, Inc.——
2996PROVAIDYA——
2997Pathways Bioscience, LLC——
2998End2End Genomics LLC——
2999Tolerance Bio Inc.—$15M
3000IMMUNOBLUE, LLC——
3001SOUVIE BIODELIVERY LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.